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Abstract
Background: Breast cancer biological characteristics change as age advances. Today, there is a lack of knowledge
regarding age-specific molecular alterations that characterize breast tumours, notably in elderly patients. The vast
majority of studies that aimed at exploring breast cancer in function of age are based on clinico-pathological data.
Gene-expression signatures (GES), which in some ways capture biological information in a non-reductionist manner,
represent powerful tools able to explore tumour heterogeneity.
Methods: Twenty-five GES were used for functional annotation of breast tumours in function of age: five for
molecular subtyping, seven for immune response, three for metabolism, seven for critical pathways in cancer and
three for prognosis. Affymetrix® genomics datasets were exclusively used to avoid cross-platform normalization
issues. Available corresponding clinico-pathological data were also retrieved and analysed.
Results: Fifteen publicly available datasets were pooled for a total of 2378 breast cancer patients (whole cohort),
out of whom 1413 were of Caucasian origin. Three age groups were defined: ≤ 40 years (AG1), > 40 to < 70 years
(AG2) and ≥ 70 years (AG3). We confirmed that age influenced the incidence of molecular subtypes. We found a
significant growing incidence of luminal B and a decreasing kinetics for basal-like in function of age. We showed
that AG3 luminal B tumours were less aggressive than AG1 luminal B tumours based on different GES (iron
metabolism, mitochondrial oxidative phosphorylation and reactive stroma), recurrence score prognostic GES
and histological grade (SBR). Contrary to tumours of young patients, tumours of elderly patients concentrated
favourable GES scores: high oestrogen receptor and mitochondrial oxidative phosphorylation, low proliferation,
basal-like, glycolysis, chromosomal instability and iron metabolism, and low GES prognostic scores (van’t Veer
70-GES, genomic grade index and recurrence score).
Conclusions: Functional annotation of breast tumours by means of 25 GES demonstrated a decreasing aggressiveness
of breast tumours in function of age. This strategy, which can be strengthened by increasing the number of
representative GES to gain more insight into biological systems involved in this disease, provides a framework to
develop rational therapeutic strategies in function of age.
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Background
Breast cancer heterogeneity makes it difficult to bring
personalized medicine into the clinic. Since many years,
research aimed at deciphering molecular presentation of
this disease to identify subgroups of patients with clinical
significance, such as prognosis or response to therapy, able
to optimize patient management. The era of large-scale
science, which is linked both to recent technological ad-
vances and to the availability of full genetic information,
has boosted the research for new biomarkers and mo-
lecular subtyping. In 2000 and 2001, Perou and Sorlie
defined five breast cancer molecular subtypes based
on gene-expression profile homologies of an intrinsic
gene list that included 427 unique genes: basal-like,
HER2-E, luminal A, luminal B, and normal breast-like
[1, 2]. They showed that these subgroups of tumours
were linked to histology, and their corresponding markers,
different natural histories, response to treatment, and
prognosis. Since these seminal studies, in breast cancer
research, numerous gene-expression signatures (GES)
with different purposes (molecular subtyping, biological
pathway exploration, prognosis) emerged. Briefly, GES
are composed of combinations of genes ranging from
few to hundreds, which in some ways capture biological
information in a non-reductionist and more informative
manner. For example, researchers demonstrated that p53
GES predicted outcome better than p53 mutation status
alone, and others showed that a signature of MYC activa-
tion, which better reflected MYC transcriptional output,
was more informative than MYC gene expression alone
[3, 4]. In breast cancer, many studies demonstrated that
GES and immunohistochemistry (IHC) were not concord-
ant, notably for triple-negative tumours [5]. Integrated
studies, combining clinico-pathological, IHC and tran-
scriptomic data, demonstrated that GES were powerful
tools to molecularly dissect breast tumours [6].
It is well recognized that breast cancer biological charac-
teristics change as age advances. Today, there is a lack of
knowledge regarding gene-expression molecular dissec-
tion of breast cancer tumours in function of age, notably
in elderly patients [7]. Age-specific molecular alterations
that characterize breast tumours remain to be elucidated.
The vast majority of studies that aimed at exploring breast
cancer in function of age are based on clinico-pathological
data. Three recent works determined intrinsic molecular
subtypes by means of PAM50 GES in function of age,
but limited their analyses only to this subtyping GES
[8–10]. In this study, we conducted functional anno-
tation of breast cancer tumours divided in three age
groups (≤40, > 40 to < 70 and ≥ 70 years) by means of 25
GES. Available clinico-pathological data (oestrogen recep-
tor [ER] status, HER2 status, nodal status [N], Scarff-
Bloom-Richardson [SBR] histological grade, tumour size
and evolution data) were analysed in parallel. Because of a
possible ethnic bias, analyses were done twice, on a whole
cohort composed of patients of mixed geographic origins,
and on a Caucasian subcohort; numbers of patients were
2378 and 1413, respectively.
Functional annotation by means of 25 GES tested in this
study demonstrated a decreasing aggressiveness of breast
tumours in function of age based on continuous GES
scoring. Furthermore, we showed that luminal B tumour
of elderly patients were less aggressive than luminal B
tumour of young patients.
Methods
Data selection
We exclusively looked for publicly available breast
cancer Affymetrix® genomic datasets associated with
clinico-pathological information, including age at diagno-
sis, prognosis and geographic origin of the cohorts in re-
positories such as Gene Expression Omnibus (GEO),
ArrayExpress, author's individual web pages, and in arti-
cles, selecting those with a medium to large sample size
[11, 12]. Among other things, our study aimed at explor-
ing molecular subtype distribution, which is known to
vary in function of population origin [10, 13–16]. For this
reason, we selected a Caucasian cohort from the whole
population. However, precise origin of the patients was ex-
ceptionally indicated in clinico-pathological characteristics
associated with genomic data. So, we selected European
cohorts and three non-European ones (E_TABM_158,
GSE7849 and GSE17907), for whom ethnicity was re-
ported; non-Caucasian patients were excluded from these
three studies. According to the cohorts’ country of origin,
we supposed that they were composed of a large majority
of Caucasian women. Patients who received neoadju-
vant chemotherapy and microdissected samples were
not included.
Data pre-processing
Data pre-processing and normalization were described
elsewhere [17] and are summarized in Additional file 1.
Gene-expression signatures
Twenty-five GES were selected for functional annotation
of breast cancer tumours. Five GES were used for breast
cancer molecular subtyping: PAM50, ER, molecular
apocrine, basal-like and claudin-CD24. Seventeen were
linked to biological processes of importance or cell types:
immune response (B-cell, interferon [IFN], interleukin-8
[IL-8], MHC-1, MHC-2, T-cell, M2-macrophages/M1-
macrophages enrichment [M2/M1]), metabolism (adipo-
cytes, glycolysis, iron [IRGS]) and critical biological path-
ways in cancer (chromosomal instability [CIN], ERBB2,
HOXA, mitochondrial oxidative phosphorylation [MITO/
OXPHOS], proliferation, reactive stroma, VEGF). Finally,
three prognostic GES were also used: van’t Veer 70-GES,
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recurrence score (RS) and genomic grade index (GGI).
Complete GES list, methods and references are briefly
described in Additional file 1.
Statistical analysis
Evolution analysis based on pejorative events (local re-
lapse, metastatic relapse or death), metastatic relapse alone
(MFS) and overall survival (OS) were estimated by the
Kaplan-Meier method and compared between the age
groups by the Log-rank test.
Mantel-Haenszel chi-square trend test was used to ana-
lyse relations between clinico-pathological characteristics
(ER, HER2, SBR histological grade, nodal status, tumour
histological size) and ordered age categories. In addition,
unordered multinomial logistic regression (UMLR) was
used for PAM50 subtype distribution and SBR histological
grade in luminal B tumours in function of continuous age.
Kinetics was determined by the value of odds ratio (OR).
One way analysis of variance (ANOVA), followed by
Tukey post-hoc test for pairwise comparisons in case of
significance, was used to compare continuous variables
between the three age groups. GES subtyping and scoring
were done on patients for whom at least 75 % of GES
genes were available in their expression data (Additional
file 1). Twenty four continuous GES (all GES except
PAM50) score correlations were illustrated with a correl-
ation plot along with the dendrogram corresponding to
average-linkage hierarchical clustering algorithm of GES
with Pearson correlation distance measure.
We considered a two-sided p-value of less than 0.05
to be statistically significant (for multiple comparisons,
Bonferroni correction was applied); the same level was
used for significance analysis of microarrays (SAM) q-
value. Mantel-Haenszel chi-square trend test, UMLR,
hierarchical clustering algorithm and SAM method were
done with R software (version 3.0.2) and packages; coin,
VGAM, amap and samr, respectively. STATA® was used
for survival analyses (version 12.0).
Results
Included patients
We exclusively focused on Affymetrix® genomic datasets to
avoid cross-platform normalization issues. Fifteen publicly
available datasets were pooled for a total of 2378 patients,
out of whom 1413 were of Caucasian origin (Table 1).
Three patients’ age groups were defined: ≤ 40 years (AG1),
> 40 to < 70 years (AG2) and ≥ 70 years (AG3). Numbers of
patients in each age group for both populations are dis-
played in Tables 2 and 3.
Clinico-pathological characteristics according to patients’
age
Associations with known clinico-pathological characteris-
tics are shown in Tables 2 and 3. A significant difference
was found for ER in function of age group (p < 0.0001)
associated with a positive kinetics. This result was in line
with current knowledge [33, 34]. A significant difference
was found for HER2 in the Caucasian cohort (p = 0.0407),
Table 1 Cohorts included in our study
n Study code Affymetrix® array References Patients n Geographic origins Caucasian n
1 E_TABM_158 HG-U133A [18] 112 USA 81
2 GSE2603 HG-U133A [19] 82 USA 0
3 GSE4922 HG-U133A + B [20] 249 Sweden 249
4 GSE6532 HG-U133A + B + Plus2 [21] 401 UK, Sweden 401
5 GSE7378 HG-U133A [22] 54 USA 0
6 GSE7390 HG-U133A [23] 198 Sweden, France, UK 198
7 GSE7849 HG-U95A [24] 75 USA 58
8 GSE9195 HG-U133Plus2 [25] 77 UK, Sweden 77
9 GSE16391 HG-U133Plus2 [26] 55 International 0
10 GSE17907 HG-U133Plus2 [27] 49 France, Tunisia 43
11 GSE19615 HG-U133Plus2 [28] 115 USA 0
12 GSE20685 HG-U133Plus2 [29] 296 Taiwan 0
13 GSE21653 HG-U133Plus2 [30] 265 France 265
14 GSE25055 HG-U133A [31] 309 USA 0
15 GSE45255 HG-U133A [32] 41 Belgium 41
Total 2378 1413
NA not available
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Table 2 Clinico-pathological characteristics according to the three patients’ age groups of the whole cohort
Patients’ group (years and [n]) n 2378 ≤40 (n = 345) 40 < x < 70 (n = 1667) ≥70 (n = 366) p-value
Age (years)
Median (IQR) 54 (45–64) 37 (34–39) 54 (47–61) 74 (72–80)
ER status
Positive 1671 (71 %) 199 (58 %) 1170 (71 %) 302 (83 %) <0.0001
Negative 681 (29 %) 143 (42 %) 477 (29 %) 61 (17 %)
HER2 status
Positive 136 (14 %) 28 (19 %) 89 (13 %) 19 (17 %) 0.4862
Negative 808 (86 %) 121 (81 %) 592 (87 %) 95 (83 %)
Nodal status
Positive 882 (43 %) 130 (49 %) 603 (42 %) 149 (44 %) 0.4010
Negative 1172 (57 %) 138 (51 %) 847 (58 %) 187 (56 %)
SBR grade
1 302 (17 %) 15 (6 %) 223 (17 %) 64 (22 %) <0.0001
2 770 (42 %) 83 (36 %) 561 (44 %) 126 (43 %)
3 742 (41 %) 134 (58 %) 504 (39 %) 104 (35 %)
Tumour size
≤20 mm 626 (46 %) 57 (44 %) 458 (48 %) 111 (42 %) 0.3993
>20 mm 723 (54 %) 72 (56 %) 499 (52 %) 152 (58 %)
Abbreviations: ER oestrogen receptor, IQR interquartile range, SBR Scarff-Bloom-Richardson histological grade
Table 3 Clinico-pathological characteristics according to the three patients’ age groups of the Caucasian cohort
Patients’ group (years and [n]) n 1413 ≤40 (n = 166) 40 < x < 70 (n = 974) ≥70 (n = 273) p-value
Age (years)
Median (IQR) 57 (47–67) 36 (33–38) 56 (49–62) 74 (72–80)
ER status
Positive 1054 (76 %) 90 (55 %) 735 (76 %) 229 (85 %) <0.0001
Negative 341 (24 %) 73 (45 %) 227 (24 %) 41 (15 %)
HER2 status
Positive 85 (23 %) 25 (36 %) 46 (19 %) 14 (22 %) 0.0407
Negative 292 (77 %) 44 (64 %) 198 (81 %) 50 (78 %)
Nodal status
Positive 498 (36 %) 62 (38 %) 319 (33 %) 117 (46 %) 0.0263
Negative 889 (64 %) 100 (62 %) 651 (67 %) 138 (54 %)
SBR grade
1 254 (19 %) 12 (8 %) 182 (20 %) 60 (24 %) <0.0001
2 571 (44 %) 57 (36 %) 403 (45 %) 111 (44 %)
3 482 (47 %) 88 (56 %) 311 (35 %) 83 (33 %)
Tumour size
≤20 mm 537 (49 %) 46 (47 %) 388 (50 %) 103 (45 %) 0.4794
>20 mm 567 (51 %) 52 (53 %) 390 (50 %) 125 (55 %)
Abbreviations: ER oestrogen receptor, IQR interquartile range, SBR Scarff-Bloom-Richardson histological grade
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with a decreasing kinetics for HER2+ in function of age
group. In Caucasian cohort, an increasing kinetics was
found for positive nodal status (N+) according to age
group (p = 0.0263) (Table 3). SBR histological grade distri-
bution was different in function of age in the two cohorts
(p < 0.0001): SBR3 decreased compared with SBR1 from
young to old patients in both cohorts. Histological size,
dichotomized based on 20 mm cut-off, did not vary. How-
ever, a difference was shown when continuous size of
tumour was used in whole cohort (p = 0.0337) and
even in Caucasian one (p = 0.0354). Histological size
was higher in AG3 compared to AG2 for Caucasian
one (p = 0.0336). Histological size and N+ status positive
kinetics in function of age were also concordant with
current knowledge [33, 35, 36].
Evolution analysis
In the whole cohort, no difference in evolution rates was
observed between the three patients’ age groups (p =
0.1265) (Fig. 1a). Similar results were found with MFS
and OS as outcomes (Additional file 2). On the contrary,
in Caucasian cohort, young patients displayed a worse
prognosis compared to patients of the intermediate group
(p = 0.0051); no difference was found between elderly pa-
tients and patients of the intermediate group (p = 0.2794)
(Fig. 1b). We have to underline that evolution analyses in
Fig. 1 Kaplan-Meier curves in function of the three patients’ age groups. a Whole cohort. b Caucasian cohort
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elderly cancer patients must be interpreted cautiously be-
cause undertreatment and comorbidities in older patients
distort them. This point will be discussed later.
Molecular dissection by means of 25 GES
Nineteen GES out of 24 continuous GES showed signifi-
cant differences (ANOVA and Tukey post-hoc test) in
function of age. ERBB2, HOXA, VEGF, Claudin-CD24 and
MHC-2 GES were never significant whatever the cohort.
GES molecular dissection results for the whole cohort and
Caucasian one are displayed in Table 4, Fig. 2 and
Additional file 3.
A total of 2378 patients were subtyped by means of
PAM50 GES. Subtype distributions are displayed in Fig. 3.
Statistical analyses showed a significant growing incidence
of luminal B in function of age (trend test: p = 0.0004 and
p < 0.0001 for whole cohort and Caucasian cohort, re-
spectively). In order to strengthen this result based on
ordered age categories, we performed UMLR, which uses
continuous age. UMLR result was concordant with trend
test (OR > 1; p < 0.05 for both cohorts). Only trend test
Table 4 Continuous GES analyses interpretation in function of three age groups
GES name Whole cohort Caucasian cohort
p-value p-value Results p-value p-value Results
1 vs 2 1 vs 3 2 vs 3 1 vs 2 1 vs 3 2 vs 3
Molecular subtyping
ER <0.0001 <0.0001 <0.0001 0.0014 1 < 2 < 3 <0.0001 <0.0001 <0.0001 0.0096 1 < 2 < 3
Molecular-
apocrine
<0.0001 <0.0001 <0.0001 0.3376 1 < 2 ≈ 3 <0.0001 <0.0001 <0.0001 0.5479 1 < 2 ≈ 3
Basal-like <0.0001 <0.0001 <0.0001 <0.0001 1 > 2 > 3 <0.0001 <0.0001 <0.0001 0.0006 1 > 2 > 3
Claudin-CD24 0.8457 NS 0.9813 NS
Immune response
B-cell <0.0001 0.7488 <0.0001 <0.0001 1 ≈ 2 > 3 0.0001 0.9398 0.0053 0.0001 1 ≈ 2 > 3
T-cell 0.0016 0.7797 0.0667 0.0010 2 > 3 1 ≈ 2 and 1 ≈ 3 0.0204 0.9736 0.1891 0.0153 2 > 3 1 ≈ 2 and 1 ≈ 3
MHC-1 0.0175 0.8578 0.0368 0.0215 1 ≈ 2 > 3 0.0300 0.6309 0.0471 0.0589 1 > 3 1 ≈ 2 and 2 ≈ 3
MHC-2 0.0133 0.0616 0.9987 0.0623 NS 0.0486 0.1769 0.9901 0.1133 NS
M2/M1 0.0136 0.3213 0.0113 0.0616 1 < 3 1 ≈ 2 and 2 ≈ 3 0.0429 0.2421 0.0341 0.2445 1 < 3 1 ≈ 2 and 2 ≈ 3
IFN 0.0067 0.3113 0.0059 0.0326 1 ≈ 2 > 3 0.0633 NS
IL-8 0.0004 0.0091 0.0003 0.0917 1 > 2 ≈ 3 <0.0001 <0.0001 <0.0001 0.3518 1 > 2 ≈ 3
Metabolism
Adipocytes 0.0118 0.0140 0.5359 0.2931 1 < 2 1 ≈ 3 and 2 ≈ 3 0.2272 NS
Glycolysis 0.0044 0.1734 0.0032 0.0418 1 ≈ 2 > 3 0.0037 0.0112 0.0031 0.4653 1 > 2 ≈ 3
IRGS 0.0013 0.0012 0.0047 0.9587 1 > 2 ≈ 3 0.0122 0.0458 0.0085 0.3879 1 > 2 ≈ 3
Critical biological pathways in cancer
CIN <0.0001 <0.0001 0.0003 0.9997 1 > 2 ≈ 3 <0.0001 <0.0001 0.0012 0.7143 1 > 2 ≈ 3
ERBB2 0.0771 NS 0.0473 0.9297 0.1280 0.0506 NS
HOXA 0.7895 NS 0.5566 NS
MITO/OXPHOS <0.0001 0.2278 <0.0001 0.0006 1 ≈ 2 < 3 0.0013 0.8029 0.0097 0.0018 1 ≈ 2 < 3
Proliferation <0.0001 <0.0001 0.0003 0.9989 1 > 2 ≈ 3 <0.0001 <0.0001 0.0013 0.9542 1 > 2 ≈ 3
Reactive stroma <0.0001 0.1912 0.0487 <0.0001 1 ≈ 2 > 3 0.0001 0.1684 0.3841 0.0001 2 > 3 1 ≈ 2 and 1 ≈ 3
VEGF 0.4340 NS 0.0743 NS
Prognosis
70-GES <0.0001 <0.0001 0.0001 0.9441 1 > 2 ≈ 3 <0.0001 <0.0001 <0.0001 0.9839 1 > 2 ≈ 3
GGI <0.0001 <0.0001 0.0008 0.9303 1 > 2 ≈ 3 0.0004 0.0003 0.0031 0.9902 1 > 2 ≈ 3
RS <0.0001 <0.0001 <0.0001 0.0006 1 > 2 > 3 <0.0001 <0.0001 <0.0001 0.0183 1 > 2 > 3
1: ≤ 40 years; 2: 40 < x < 70 years; 3: ≥ 70 years; ER oestrogen receptor, IFN interferon, IRGS iron regulatory gene signature, CIN chromosomal instability,
MITO/OXPHOS mitochondrial oxidative phosphorylation, NS not significant (p > 0.05), 70-GES van’t Veer and colleagues prognostic GES, GGI genomic grade index,
RS recurrence score
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was significant for growing incidence of luminal A for
whole cohort (p = 0.0092). A decreasing kinetics for basal-
like was found for the whole cohort (trend test: p < 0.0001;
UMLR: OR < 1; p < 0.0060) and for the Caucasian one
(trend test: p < 0.0001; UMLR: OR < 1; p < 0.0005). No
other age-related kinetics was found for other subtypes. It
Fig. 2 Molecular dissection of breast cancer tumours in function of age. Average hierarchical clustering and heatmap showing the segregation of
three age groups as a function of 24 GES scores. a Whole cohort. b Caucasian cohort. These figures are illustrations of table 4 statistical analyses.
First row presents the three age groups: ≤ 40 years (a, n = 345; b, n = 166) (sky blue), 40 < x < 70 years (a, n = 1667; b, n = 974) (medium blue)
and≥ 70 years (a, n = 366; b, n = 273) (dark blue), from left to right. Other rows, from top to bottom, present PAM50 GES subtyping (basal-like
(red); HER2-E (purple); luminal A (dark blue); luminal B (sky blue); normal breast-like (green); unclassified (yellow)) and GES scores in function of
age (green: low score; red and green grid pattern: intermediate score; red: high score; sky blue: not significant or not interpretable)
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is a bit surprising to notice an increasing incidence of
luminal B, which is known to be a bad prognostic subtype,
because breast cancer in advanced age has been associated
with a slightly increased probability of favourable tumour
biology [33]. Aggressive subtypes should be underrep-
resented and, on the contrary, less aggressive subtypes
should be overrepresented; as we found, basal-like kinetics
was in agreement with this. One hypothesis could be that
luminal B tumours of elderly patients are less aggressive
than those of younger patients. To explore this hypothesis,
we evaluated SBR histological grade distribution in lu-
minal B tumours in function of age (Fig. 4). We chose to
conduct analysis with only SBR1 (less aggressive) and
SBR3 (high aggressive) because clinical interpretation of
SBR2 is complicated. Analyses showed that SBR1 percent-
age increased and SBR3 decreased in function of age in
luminal B tumours in whole cohort (trend test: p = 0.0168;
UMLR: OR = 0.96, p = 0.0035) and even in Caucasian co-
hort (trend test: p = 0.0259; UMLR: OR = 0.95, p = 0.0042),
which was consistent with our hypothesis. Furthermore,
GES analyses of patients belonging to AG1 and AG3
showed an “AG1 >AG3” profile for reactive stroma, IRGS
and RS, and an “AG1 < AG3” profile for MITO/OXPHOS,
which testifies to the aggressiveness of AG1 luminal B
tumours compared to AG3 luminal B tumours, in both
cohorts or in the whole cohort (Additional file 4). Evolu-
tion analysis of luminal B patients in function of the three
age groups did not show any difference (whole cohort:
p = 0.7717; Caucasian cohort: p = 0.3969). For reasons
cited above (evolution analyses biases in elderly) and dis-
cussed later, this result did not invalidate our hypothesis.
ER GES showed an increasing kinetics in function of
age groups as demonstrated above by means of IHC-
measured ER. Molecular apocrine scores were the smallest
in young patients and higher in the two other age groups
suggesting an increased androgen receptor signalling in
these last ones. This finding was concordant with some
studies based on IHC, which indicated a higher rate of
apocrine carcinoma in elderly and a correlation with meno-
pausal status [37, 38]. Molecular apocrine GES scores often
clustered with ER (Additional file 3). Basal-like GES scores
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Fig. 3 Distribution of the five PAM50 molecular subtypes in function of age. a Whole cohort. b Caucasian cohort
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the same decreasing kinetics was found in function of
age groups.
Molecular dissection of the three age groups by means
of seventeen GES linked to biological processes of import-
ance or cell types showed concordant results in both co-
horts for B-cell (AG1 ≈AG2 > AG3), T-cell (AG2 >AG3),
IL-8, IRGS, proliferation and CIN (AG1 >AG2 ≈AG3),
MITO/OXPHOS (AG1 ≈AG2 <AG3), and M2/M1 (AG1
<AG3) (Table 4). When focusing only on the two extreme
age groups, there were more concordant results between
the two cohorts: basal-like, B-cell, MHC-1, IL-8, CIN, pro-
liferation, glycolysis and IRGS displayed an “AG1 >AG3”
profile, whereas ER, molecular apocrine, MITO/OXPHOS
and M2/M1 displayed an “AG1 < AG3” profile.
Immune response (IR) evaluated by B-cell, MHC-1
and IL-8 GES was lower in elderly patients for both
cohorts. This result could be due to immunosenescence,
which was demonstrated in different transcriptomic
works, rather than local low IR or local immunosuppres-
sion [39, 40]. Here, we showed that IL-8 and basal-like
always clustered together (Additional file 3). IL-8, member
of the CXC chemokine family of angiogenesis/inflamma-
tion-related chemokines, is overexpressed in breast cancer,
is linked to bad prognosis, has a direct role in angiogenesis
and is involved in cancer stem-like cells (CSC) regulation
[41, 42]. Because CSC are associated with basal-like sub-
type in breast cancer, IL-8/basal-like cluster might indir-
ectly illustrate IL-8/CSC biological pathway [43]. M2/M1
showed an opposite result: high score in elderly patients
(AG1 < AG3). In a recent study, which aimed at subtyping
triple negative breast cancer (TNBC) tumours, we found
that IR was associated with good prognosis in a basal-like-
and claudin-low-enriched TNBC subtype [6]. On the
contrary, M2/M1 high scores, meaning enrichment in M2
pro-tumourigenic macrophages were associated with a
bad prognosis for pure basal-like TNBC subtype. M2/M1
GES applied on TNBC and PAM50 basal-like patients of
our study failed to reach significance in whole cohort (p =
0.3722; AG1 = 36, AG2 = 149, AG3 = 21) and in Caucasian
cohort (p = 0.3166; AG1 = 8, AG2 = 46, AG3 = 12). This
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Fig. 4 SBR histological grade distribution in luminal B tumours in function of age. a Whole cohort. b Caucasian cohort
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Elderly patients had the lowest stromal reaction for the
whole cohort and a lower stromal reaction compared to
the intermediate age group for Caucasian one. This meta-
gene captured different clinico-biological information. Its
pattern of expression is similar to that of mammospheres
and epithelial to mesenchymal signature metagene and is
associated with chemoresistance [44]. A weak correlation
was found for reactive stroma and adipocytes GES scores
(Additional file 3).
70-GES and GGI scoring displayed an “AG1 > AG2 ≈
AG3” profile and RS scoring an “AG1 > AG2 > AG3”
profile, respectively. In the first case, AG1 was the worst
prognostic group. In the second case, a decreasing prog-
nostic kinetics was shown, starting with AG1 as the
worst prognosis age group and ending with AG3 as the
best prognosis age group. RS score results might confirm
the negative effect of different and less effective thera-
peutic management compared with younger patients on
survival of elderly patients, which, despite best prognostic
scores, is not significantly different from AG1 patients’
survival, neither in whole cohort, nor in Caucasian one
(while, in the latter cohort, AG2 patients’ survival is sig-
nificantly better than AG1 patients’) (Fig. 1). Furthermore,
70-GES, GGI and RS clustered strongly with proliferation
(Additional file 3). This can be explained by the fact that
proliferation is the common driving force of these prog-
nostic GES [45, 46].
GES analyses interpretation in function of ER status in
the three age groups confirmed that proliferation (prolif-
eration GES, 70-GES, GGI and RS) was of no value in
predicting aggressiveness and prognosis in ER-negative
breast cancer tumours (Additional file 5) [45].
SAM analysis identified 1116 genes with statistically
significant changes in expression between the two extreme
age-groups, AG1 and AG3: 432 overexpressed and 684
underexpressed genes in AG3 [47]. GO biological process
enrichment analyses of these two gene lists by means of
ToppGene web tool showed that cell cycle and cell migra-
tion, which are considered as basal-like hallmark, charac-
terized AG1, and that oxidation-reduction process and
lipid metabolism, which are considered as luminal hall-
mark, characterized AG3 (Additional file 6) [48, 49].
Although these non-hypothesis-driven results might be
seen as too overly broad, they corroborated GES mo-
lecular dissection of breast tumours in function of age.
Discussion
Functional annotation may be separated into two ways
of analyses: a quantitative one by means of GES, which
assigns scores to patients, and a qualitative one based on
gene lists, which assigns a “Gene Ontology” enrichment
score to a cluster representative gene list [49].
In this work, we focused on GES scoring and used
“Gene Ontology” enrichment score to corroborate our
findings. Functional annotation according to the three age
groups by means of clinico-pathological data was done to
confirm that our cohort was representative of breast
cancer population. Because of a possible ethnic bias, ana-
lyses were done twice: on the whole cohort and on the
Caucasian one. Finally, there were only slight differences
between whole cohort results and Caucasian results.
Statistical comparisons could not be done because these
cohorts were not independent.
GES used in our study can be classified into different
categories: molecular subtyping (n = 5), immune response
(n = 7), metabolism (n = 3), critical biological pathways in
cancer (n = 7) and prognosis (n = 3). One question that
emerged is potential biological redundancy between GES.
Except for prognosis GES (70-GES, RS and GGI), CIN
and PAM50, which are enriched in proliferation genes,
other GES captured different biological information based
on varying pathways. Numbers of genes in common be-
tween these last GES are equal or close to zero (Additional
file 7). Except M2/M1 GES all other IR GES have no genes
in common. However it is well known that different
combination of genes can capture the same biological
information. In order to look for overlapping biological
information, we compared GO enrichment terms (bio-
logical process tree) linked to each GES’s gene list (Fisher's
exact test; p < 0.01). Results are displayed in Additional
files 8 and 9. Only a few remarks can be made. In some
cases, limited GES similarities exist and are concordant
with biological knowledge. Biological process similarities
emerged for IR GES (B-cell, IFN, IL-8, MHC-1, MHC-2
and T-cell) and as expected for GES enriched in prolifera-
tion genes (Proliferation, GGI, CIN, PAM50, RS and 70-
GES). Another biological process cluster is found for ER,
RS, Molecular apocrine and PAM50. RS and PAM50 are
strongly dependent on ER pathway. Out of 16 cancer
genes included in RS GES, four belong to ESR1 cluster:
ESR1, PGR, BCL2 and SCUBE2. Link between ER and
molecular apocrine GES is explained by the fact that
molecular apocrine subtype has a gene expression profile
resembling that of ER-positive tumours [50, 51]. Our
strategy might be improved by enriching GES list. Fo-
cusing on other and non-redundant critical biological
pathways in cancer and increasing breast tumour tran-
scriptome deconvolution will certainly enhance molecular
dissection performance.
Molecular dissection by means of GES tested in this
study confirmed that breast cancer tumours of young
patients were more aggressive than tumours of older pa-
tients. Furthermore, we showed that tumour aggressive-
ness decreased regularly in function of age groups based
on continuous GES scoring. Finally, tumours of elderly
patients concentrated favourable GES scores: high ER,
MITO/OXPHOS, low proliferation, basal-like, glycolysis,
CIN and IRGS, and low GES prognostic score (70-GES,
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GGI and RS). These biological features were not linked
to favourable disease evolution, but this result must be
interpreted cautiously in elderly patients. Undertreat-
ment in older patients with breast cancer is known to
have a strong negative effect on survival [36, 52–54].
Furthermore, in our study, evolution criteria were: local
relapse, metastatic relapse, or death. Due to non-cancer-
related death linked to comorbidity, which we could not
identify, this last pejorative event is likely higher in eld-
erly patients and may significantly skew evolution ana-
lyses [55]. One study reported that 44 % of undertreated
elderly patients died during follow-up period without
disease recurrence [54].
We confirmed that age influences the incidence of
molecular subtypes and found a significant growing inci-
dence of luminal B and a decreasing kinetics for basal-
like in function of age. As we underlined, luminal B
kinetics was surprising, but concordant with Jenkin’s and
de Kruijf ’s studies [8, 9]. On the contrary, Sweeney and
colleagues found an opposite result [10]. In this work,
we showed that AG3 luminal B tumours were less aggres-
sive than AG1 luminal B tumours based on SBR histo-
logical grade and four GES (IRGS, MITO/OXPHOS,
reactive stroma and RS). Our results are concordant with
an IHC study conducted by Morrison and colleagues [56].
They found high proliferation (Ki67 > 14 %), high mutated
P53 (≥10 %) and high Nottingham grade in young luminal
B (≤40 years) compared to older luminal B patients
(≥50 years). At this time, it is premature to definitively
conclude and additional studies will be necessary to con-
firm these results.
In our study, the GES molecular dissection with the
most complicated results interpretation were those pro-
vided by IR GES. An “AG1 > AG3” profile was found for
B-cell, MHC-1 and IL-8, an “AG2 > AG3” for T-cell in
both cohorts, and an “AG1 ≈AG2 > AG3” for IFN for
whole cohort. Aside from M2/M1 scores, when focusing
only on the two extreme age groups, these results dem-
onstrated a high IR in young patients and a low IR in
elderly patients. Immunity is known to play a dual role
in the complex interactions between tumours and the
host. In established cancer, some immune cells are known
to induce anti-tumoural effects (immunosurveillance) (NK
cells, CD8+ T cells, Th1 cells, dendritic cells 1, M1 macro-
phages…), and others, pro-tumoural effects (myeloid-
derived suppressor cells, CD4+ T cells, Th2 cells, dendritic
cells 2, M2 macrophages…) [57-59]. A dynamic model,
called “immunoediting”, more appropriately emphasizes
the dual roles of immunity and describes tumour and im-
mune system interactions in a chronological three phase
process: elimination (immunosurveillance), dynamic equi-
librium and escape [60, 61]. The disruption of this equilib-
rium results from Darwinian selection of a new population
of tumour clones able to escape from immune detection
and/or elimination, allowing tumour progressive growth
and dissemination. A second level of complexity is due to
an age-dependent general decline of immune function that
has been termed immunosenescence, which is associated
with high circulating level of pro-inflammatory cytokines.
As a consequence of these facts, most obvious, reductionist
and parsimonious questions which can be asked are: In
elderly patients, is low intra-tumoural IR principally due to
a local effect of immunosenescence? In young patients with
high intra-tumoural IR, does bad prognosis depend in part
upon IR escape as proposed in immunoediting dynamic
model? In answering these questions, we will be able to
progress in the selection of immunotherapy strategies in
function of age.
Conclusions
Our study demonstrated that a panel of GES may be used
to decipher the heterogeneity of breast cancer in function
of age and represented a preliminary work. A GES list
including most of relevant biological pathways in breast
cancer will certainly help to gain more insight into bio-
logical systems involved in this disease and will provide a
framework to develop rational therapeutic strategies based
on meaningful subtyping. We believe that GES are effi-
cient tools able to dissect tumours because they do not
depend on only one prototypic marker, but are composed
of a combination of genes involved and/or correlated to a
particular molecular pathway, and for this reason, capture
more efficiently biological information.
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